Recent developments in synthetic oligosaccharide-based bacterial vaccines
- PMID: 18289082
- DOI: 10.2174/156802608783378864
Recent developments in synthetic oligosaccharide-based bacterial vaccines
Abstract
Synthetic advances made possible chemical assembly of complex oligosaccharide fragments of polysaccharide domains on the surface of human pathogenic bacteria. These oligosaccharides may be recognized by antibodies raised against high molecular weight, native, polysaccharides. In addition to their antigenicity, synthetic oligosaccharides can also function as haptens in their protein conjugates that can elicit not only oligo- but also polysaccharide-specific IgG antibodies in animal models and in humans. A major milestone in the development of new generation vaccines was the demonstration that protein conjugates of synthetic fragments of the capsular polysaccharide of Haemophilus influenzae type b are as efficacious in preventing childhood meningitis and other diseases as is the corresponding licensed commercial vaccine containing the bacterial polysaccharide. The lessons learnt in this and other endeavors described herein are manifold. For example, they teach us about the significance of the oligosaccharide epitope size, the number of their copies per protein in the conjugate, the possible effect of the spacer on anti-saccharide immune response, and the proper choice of the carrier protein combined with the selection of the animal model. The H. influenzae b story also teaches us that that the synthetic approach can be commercially viable.
Similar articles
-
Antigenicity and immunogenicity of a synthetic oligosaccharide-protein conjugate vaccine against Haemophilus influenzae type b.Infect Immun. 2004 Dec;72(12):7115-23. doi: 10.1128/IAI.72.12.7115-7123.2004. Infect Immun. 2004. PMID: 15557635 Free PMC article.
-
Effect of oligosaccharide chain length, exposed terminal group, and hapten loading on the antibody response of human adults and infants to vaccines consisting of Haemophilus influenzae type b capsular antigen unterminally coupled to the diphtheria protein CRM197.J Immunol. 1989 Apr 1;142(7):2464-8. J Immunol. 1989. PMID: 2784464
-
Response of 7- to 15-month-old infants to sequential immunization with Haemophilus influenzae type b-CRM197 conjugate and polysaccharide vaccines.Am J Dis Child. 1991 Aug;145(8):898-900. doi: 10.1001/archpedi.1991.02160080076024. Am J Dis Child. 1991. PMID: 1858727 Clinical Trial.
-
Further approaches for optimizing polysaccharide-protein conjugate vaccines for prevention of invasive bacterial disease.J Infect Dis. 1992 Jun;165 Suppl 1:S156-9. doi: 10.1093/infdis/165-supplement_1-s156. J Infect Dis. 1992. PMID: 1588152 Review.
-
Semi- and fully synthetic carbohydrate vaccines against pathogenic bacteria: recent developments.Biochem Soc Trans. 2021 Nov 1;49(5):2411-2429. doi: 10.1042/BST20210766. Biochem Soc Trans. 2021. PMID: 34495299 Free PMC article. Review.
Cited by
-
Synthetic oligosaccharides as tools to demonstrate cross-reactivity between polysaccharide antigens.J Org Chem. 2012 Jul 20;77(14):5922-41. doi: 10.1021/jo300299p. Epub 2012 Jun 29. J Org Chem. 2012. PMID: 22713129 Free PMC article.
-
Convergent synthesis of the tetrasaccharide repeating unit of the cell wall lipopolysaccharide of Escherichia coli O40.Beilstein J Org Chem. 2012;8:2053-9. doi: 10.3762/bjoc.8.230. Epub 2012 Nov 22. Beilstein J Org Chem. 2012. PMID: 23209539 Free PMC article.
-
Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part II: Vaccines for Shigella, Salmonella, enterotoxigenic E. coli (ETEC) enterohemorragic E. coli (EHEC) and Campylobacter jejuni.Hum Vaccin Immunother. 2015;11(3):601-19. doi: 10.1080/21645515.2015.1011578. Hum Vaccin Immunother. 2015. PMID: 25715096 Free PMC article. Review.
-
Opportunities and challenges in synthetic oligosaccharide and glycoconjugate research.Nat Chem. 2009 Nov;1(8):611-22. doi: 10.1038/nchem.399. Nat Chem. 2009. PMID: 20161474 Free PMC article. Review.
-
Immunochemical characterization of synthetic hexa-, octa- and decasaccharide conjugate vaccines for Vibrio cholerae O:1 serotype Ogawa with emphasis on antigenic density and chain length.Glycoconj J. 2013 Dec;30(9):871-80. doi: 10.1007/s10719-013-9491-9. Epub 2013 Aug 17. Glycoconj J. 2013. PMID: 23955520 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources